Hernández LV, Toledo BI, Sánchez ÁF, López LG, Vadillo BM

Idioma: Español
Referencias bibliográficas: 66
Paginas: 170-175
Archivo PDF: 114.28 Kb.

RESUMEN

La homocisteína es producto del metabolismo intermediario para la producción de cisteína; se forma por demetilación de metionina y se elimina por remetilación y transulfuración, ambas reacciones dependientes de vitamina B12 y B6, además contiene un grupo tiol que le permite reaccionar con moléculas biológicamente importantes. La hiperhomocisteinemia es un factor de riesgo para enfermedad vascular, está relacionada con la secreción de insulina, especialmente en pacientes diabéticos y es potencialmente modificable con sustitución vitamínica. No se ha demostrado el mecanismo preciso para el daño vascular que origina; sin embargo, la exposición de células endoteliales, aun a concentraciones mínimas de homocisteína, disminuye la respuesta de vasodilatación endotelial, produce una cascada inflamatoria y aumenta la expresión de receptores para los productos finales de la glucosilación enzimática, estas reacciones pueden alterar la función de enzimas, receptores, factores de crecimiento y proteínas estructurales.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Encuesta Nacional de las Enfermedades Crónico-degenerativas. S.S.A. México, 1993.

2. Tapia CR, Olaiz G. Los retos de la transición. Hipertensión, diabetes y enfermedades cardiovasculares. Cuadernos de Salud. S.S.A. México, 1994.

3. Bronfman M. Un reto más hacia el futuro. La salud de la población de edad avanzada. Cuadernos de Salud. S.S.A. México, 1994.

4. Escobedo-De La Peña J, Rico-Verdín B. Incidencia y letalidad de las complicaciones agudas y crónicas de la diabetes mellitus en México. Salud Pública Méx 1996; 38: 236-242.

5. Encuesta Nacional de las Enfermedades Crónico-degenerativas. S.S.A. México, 1996.

6. White F. La Diabetes en las Américas. Evaluación inicial de las respuestas nacionales de Organización Panamericana de la Salud, 1997.

7. Fonseca V, Dicker-Brown A, Ranganathan S, Song W, Barnard RJ, Fink L, Kern PA. Effects of a high-fat-sucrose diet on enzymes in homocysteine metabolism in the rat. Metabolism 2000; 49: 736-741.

8. Munshi MN, Stone A, Fink L, Fonseca V. Hyperhomocysteinemia following A methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism 1996; 45: 133-135.

9. Das S, Reynolds T, Patnaik A, Rais N, Fink LM, Fonseca VA. Plasma homocysteine concentrations in type II diabetic patients in India: relationship to body weight. J Diabetes Complications 1999; 13: 200-203.

10. Chico A, Perez A, Cordoba A, Arcelus R, Carreras G, De Leiva A, Gonzalez-Sastre F, Blanco-Vaca F. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetología 1998; 41: 684-693.

11. Hajjar KA. The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen. J Biol Chem 1991; 266: 21962-21970.

12. Drzewoski J, Czupryniak L, Chwatko G, Bald E. Hyperhomocysteinemia in poorly controlled type 2 diabetes patients. Diabetes Nutr Metab 2000; 13: 319-324.

13. Brown WV. Risk factors for vascular disease in patients with diabetes. Diabetes Obes Metab 2000; 2(Suppl 2): S11-18.

14. Baliga BS, Reynolds T, Fink LM, Fonseca VA. Hyperhomocysteinemia in type 2 diabetes mellitus: cardiovascular risk factors and effect of treatment with folic acid and pyridoxine. Endocr Pract 2000; 6: 435-441.

15. Salardi S, Cacciari E, Sassi S, Grossi G, Mainetti B, Dalla CC, Pirazzoli P, Cicognani A, Gualandi S. Homocysteinemia, serum folate and vitamin B12 in very young patients with diabetes mellitus type 1. J Pediatr Endocrinol Metab 2000; 13: 1621-1627.

16. Jager A, Kostense PJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Donker AJ, Stehouwer CD. Serum homocysteine levels are associated with the development of (micro) albuminuria: The Hoor Study. Arterioscler Thromb Vasc Biol 2001; 21: 74-81.

17. Bremner WF, Holmes EW, Kanabrocki EL, Hermida RC, Ayala D, Garbincius J, Third JL, Ryan MD, Johnson M, Foley S, Shirazi P, Nemchausky BA, Scheving LE. Circadian rhythm of serum total homocysteine in men. Am J Cardiol 2000; 15: 1153-1156.

18. Hoogeveen EK, Kostense PJ, Eysink PE, Polak BC, Beks PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: The Hoorn Study. Arch Intern Med 2000; 160(19): 2984-2990.

19. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burder associated with overweight and obesity. JAMA 1999; 282: 1523-1529.

20. Fonseca V, Guba SC, Fink LM. Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. Endocr Rev 1999; 20: 738-759.

21. Hajjar KA. Homocysteine: a sulph’rous fire. J Clin Invest 2001; 107: 663-664.

22. Guillian LB, Elaine EL. Wang with the Canadian Task Force on Preventive Health Care. Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. CMAJ 2000; 163: 21-29.

23. Mc Cully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-128.

24. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395-1398. 174 Víctor Hernández López et al. Homocisteína y enfermedad vascular en diabetes mellitus tipo 2

25. Glueck CJ, Shaw P, Lang JE, Tracy T, Sieve-Smith L, Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995; 75: 132-136.

26. Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D’Agostino RB, Wilson PW, Wolf PA. Nonfasting plasma total homocysteine levels and all-cause and stroke incidence in elderly persons: The Framingham study. Ann Intern Med 1999; 131: 352-355.

27. Nigard O, Nordrehang JE, Refsum H, Veland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-236.

28. Harjai KL. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein (a), triglicerides, oxidative stress and fibrinogen. Ann Intern Med 1999; 131: 376-386.

29. Domagala TB, Undas A, Libura M, Szczeklik A. Pathogenesis of vascular disease in hyperhomocysteinemia. J Cardiovasc Risk 1998; 4: 239-247 (Abstract).

30. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881.

31. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA, den Heijer M, Trijbels FJ, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.

32. Motulsky AG. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet 1996; 58: 17-20.

33. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862-867.

34. Dalery K, Lussier-Cacan S, Selhub J, Davignon J, Latour Y, Genest Jr J. Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate. Am J Cardiol 1995; 75: 1107-1111.

35. Selhub J, Jacques PR, Bostom AG, D’Agostino RB, Wilson PW, Belanger AJ, O’Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-291.

36. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.

37. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-1155.

38. Den HM, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vanderbroucke JP, Rosendal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-762.

39. Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jakobs C, Fowler B, Seligsohn U. Coexistence of hereditary homocystinuria and factor V Leiden-effect on thrombosis. N Engl J Med 1996; 334: 763-768.

40. Graham IM, Daly LE, Refsum HM, Robinson K. The European Concerted Action Project. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997; 277: 1775-1781.

41. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocysteine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947-1953.

42. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, Hess DL, Davis CE. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998; 98: 204-210.

43. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881.

44. Arnesen E, Refsun H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704-709.

45. Alfthan G, Pekkanen J, Jauhiainen M, Pitkäniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9-19.

46. Chasan-Taber L, Selhub J, Rosenberg IH, Malinow R, Terry P, Tishler PV, Willett W, Hennekens CH, Stampfer MJ. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996; 15: 136-143.

47. Verhoef P, Hennekens CH, Allen RH, Stabler SP, Willett WC, Stampfer MJ. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol 1997; 79: 799-801.

48. Nigard O, Nordrehang JE, Refsum H, Veland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-236.

49. Fauci A, Harrison RG, Wilson JD, Braunwald E, Harrison KJ. Principios de Medicina Interna 13a Ed. McGraw-Hill. Madrid, España, 1997.

50. Robert KM, Peter AM, Daryl K, Victor WR. Bioquímica de Harper 14a Ed. Manual Moderno. México, DF, 1997.

51. Mathews CK, Van Holde KE. Metabolismo de los compuestos nitrogenados: Principios de la biosíntesis la utilización y el recambio. En Mathews CK, Van Holde KE eds. Bioquímica. 2a Ed. McGraw-Hill. Madrid, España, 2000; 807-830.

52. Mudd Sh, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver Cr, Beaudet Al, Sly Ws, Valle D. The metabolic basis of inherited diseases, Ed 7. McGraw-Hill, New York, 1995: 1279-1327.

53. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992; 55: 131-138.

54. Guba S, Fink L, Fonseca V. Hyperhomocysteinemia-An emerging and important risk factor for thromboembolic and cardiovascular disease. Am J Clin Pathol 1996; 106: 709-722.

55. Loehrer FMT, Angst CP, Haefeli WE, Jordan PP, Ritz R, Fowler B. Low whole-blood S-adenosylmethionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease. Arterioscler Thromb Vasc Biol 1996; 16: 727-733.

56. Jencks DA, Matthews RG. Allosteric inhibition of methylenetetra-hydrofolate reductase by adenosylmethionine. Effect of adenosylmethionine and NADPH on the equilibrium between active and inactive forms of the enzyme and on the kinetics of approach to equilibrium. J Biol Chem 1987; 262: 2485-2493.

57. Finkelstein JD, Kyle WE, Martin JL, Pick AM. Activation of cystathionine synthase by adenosylmethionine and adenosylethionine. Biochem Biophys Res Commun 1975; 66: 81-87.

58. Jocelyn PC. Biochemistry of the SH group. Academic Press. 1972. New York, NY.

59. Krumdieck C, Prince C. Mechanisms of homocysteine toxicity on connective tissues: implications for the morbidity of aging. American Society for Nutritional Sciences 2000: 365-368 (Sppl).

60. McDowell I, Lang D. Homocysteine and endothelial dysfunction: a link with cardiovascular diseases. American Society for Nutritional Sciences 2000: 369-72 (Suppl).

61. Ling Q, Hajjar K. Inhibition of endothelial cell tromboresistance by homocysteine. American Society for Nutritional Sciences 2000: 373-376 (Suppl).

62. Emoto M, Kanda H, Shoji T, Kawagishi T, Komatsu M, Mori K, Tahara H, Ishimura E, Inaba M, Okuno Y, Nishizawa Y. Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care 2001; 24: 533-538.

63. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method to quantifying insulin secretion and resistance. Am J Physiol 1979; 237: 214-223.

64. Sheu WH, Lee WJ, Chen YT. Plasma homocysteine concentrations and insulin sensitivity in hypertensive subjects. Am J Hypertens 2000; 13: 14-20.

65. McCarty. Insulin secretion as a potential determinant of homocysteine levels. Med Hypotheses 2000; 55: 454-455.

66. Undas A, Domagala TB, Jankowski M, Szczeklik A. Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation. Throm Res 1999; 95: 218-228.